Shots:
Priya spoke about the study design and key findings from the P-II (LILAC), P-III (TOPAZ-1) & (TOPAZ-2) clinical study evaluating litifilimab
She also talked about the P-III trial evaluating Dapirolizumab pegol in collaboration with UCB to treat SLE
The interview summarizes how Biogen’s innovative medications are helping patients with Systemic Lupus Erythematosus which has…
Shots:
Patrick spoke about the 3-month data from the First-in-Human glaucoma treatment trial of Spyglass’ innovative drug delivery platform that helps in lowering intraocular pressure in patients with glaucoma or ocular hypertension
Patrick also talked about the study design and key findings from the First-in-Human glaucoma treatment trial
The interview gives an understanding of Spyglass’…
Shots:
Tim spoke about the development of THE-349, a fourth-generation small molecule for the treatment of EGFR-mutant NSCLC
Tim also talked about Thesus’ other small molecule, THE-630 in gastrointestinal stromal tumors (GIST) being evaluated in a P-I/II dose-escalation and expansion study
The interview gives an understanding of how Thesus is developing different treatment options to…
Active Ingredient: rivaroxaban
Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg
Dosage Form: Tablets
Mechanism of Action: Factor Xa inhibitors
First Approval: US (1 Jul 2011), EU (30 Sep 2008)
Revenue Analysis of Xarelto1
Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…
Shots:
Dr. Navdeep spoke about the data presented at the ASN Kidney Week 2022 emphasizing on the urgent need for early screening of chronic kidney disease
Helen Yeh talked about the treatment of CKD with Farxiga. She also focused on the patient support programs by AstraZeneca for the early diagnosis and screening of patients
The…
Shots:
Emily spoke about the launch of the new visual identity of Merz Aesthetics. The identity is built on the idea to create a cohesive and clear visual identity for Merz Aesthetics that reflects who they are and the purpose to fuel confidence
The brightness of this new identity includes shades of orange, yellow, green,…
Shots:
Dr. Susan talked about the results from the SOLO-1 P-III trial of Lynparza in patients with BRCA mutated (BRCAm) newly diagnosed advanced ovarian cancer presented at ESMO’22
Dr. Susan also spoke about the overall survival of this 7-year follow-up study.The 7-year follow-up of SOLO-1 showed that olaparib provided a clinically meaningful improvement in OS…
Shots:
Bill spoke about Respiratory Syncytial Virus and how it can severely affect infants' health
Bill also talked about the 14 studies on RSV published in the Journal of Infectious Diseases (JID)
The interview gives an understanding of how Sanofi’s vision to develop innovative solutions to help reduce the burden of RSV on infants, families,…
Shots:
Simon spoke about the new data on FETROJA (cefiderocol), an antibiotic for the treatment of serious Gram-negative (highly resistant) bacterial infections
He also talked about Shionogi’s agreement with GARDP & CHAI for the manufacturing and commercialization of cefiderocol in different countries
The interview summarizes how Shionogi is advancing by developing medicines to treat serious…
Shots:
Martin gave a detailed view of the newly launched Honey Analytics module associated with the Trialbee Honey™ platform
He also talked about the how Trialbee Honey platform will help in the screening and recruiting of patients specifically in remote areas
The interview gives a profound understanding of how Trialbee is developing real-time monitoring modules…

